Jocasta Neuroscience is a biotechnology company focused on cognitive health and aging, pursuing science-backed approaches to protect and enhance brain function. The company investigates the therapeutic potential of the Klotho protein and KL-VS genetic variants to improve memory, cognitive resilience, and overall brain aging, with preclinical data in primates and plans for human trials. Led by experts in cognitive health and aging, Jocasta emphasizes early-stage development of KL-targeted therapies, including the JN-0413 formulation. The organization envisions advancing longevity-focused neurology and dementia prevention, with research updates and potential clinical programs in the near term.
No recent news for this company.
No recent deals for this company.